ArticleFEBS open bio2022

Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates.

Yingying Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.